Cancer therapy–related hypertension: a scientific statement from the American Heart Association
JB Cohen, NJ Brown, SA Brown, S Dent… - …, 2023 - Am Heart Assoc
Contemporary anticancer drugs have significantly improved cancer survival at the expense
of cardiovascular toxicities, including heart disease, thromboembolic disease, and …
of cardiovascular toxicities, including heart disease, thromboembolic disease, and …
Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy
Y Zheng, S Huang, B ** atrial fibrillation (AF) and thrombosis.
However, the management of anticoagulation in patients with both diseases may be …
However, the management of anticoagulation in patients with both diseases may be …
[HTML][HTML] Cardiotoxicity of chemotherapy and targeted agents
TW Mudd Jr, M Khalid, AK Guddati - American Journal of Cancer …, 2021 - ncbi.nlm.nih.gov
The evolution of cancer treatment and development of new classes of anticancer therapies
have continued to revolutionize the field of oncology. New therapies including targeted …
have continued to revolutionize the field of oncology. New therapies including targeted …
Non-hematologic toxicity of bortezomib in multiple myeloma: The neuromuscular and cardiovascular adverse effects
Simple Summary Multiple myeloma (MM) is a still uncurable tumor of mainly elderly patients
originating from the terminally differentiated B cells. Introduction to the treatment of MM …
originating from the terminally differentiated B cells. Introduction to the treatment of MM …
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials
We aim to determine the cumulative and comparative risk of cardiovascular events
associated with different Immunomodulatory Drugs (iMiDs) and Proteasome Inhibitor (PIs) in …
associated with different Immunomodulatory Drugs (iMiDs) and Proteasome Inhibitor (PIs) in …
Arterial hypertension in cancer: The elephant in the room
The great therapeutical success achieved by oncology is counterbalanced by growing
evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac …
evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac …
Cardiovascular toxicity of carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States
Y Zhai, X Ye, F Hu, J Xu, X Guo, Y Cao, Z Lin… - Frontiers in …, 2021 - frontiersin.org
Background: Carfilzomib, an effective proteasome inhibitor agent for the therapy of relapsed
and refractory multiple myeloma, has been related to a significant number of cardiovascular …
and refractory multiple myeloma, has been related to a significant number of cardiovascular …
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein
TW Jenkins, SL Downey-Kopyscinski, JL Fields… - Scientific Reports, 2021 - nature.com
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …
MicroRNAs in cancer treatment-induced cardiotoxicity
L Pellegrini, S Sileno, M D'Agostino, E Foglio… - Cancers, 2020 - mdpi.com
Cancer treatment has made significant progress in the cure of different types of tumors.
Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the …
Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the …